A neurodegenerative disease and the case for cell therapy
Quick answer
PDSTEM inj. is EHL Bio's cell therapy candidate for Parkinson's disease, using the patient's own adipose MSCs by repeat intravenous infusion. It is currently in non-clinical study. The rationale is neuroprotection and reduced neuroinflammation rather than direct transplantation of dopaminergic cells as in embryonic stem cell research.
Parkinson's stems from degeneration of dopamine-producing neurons in the substantia nigra, causing resting tremor, bradykinesia, rigidity and postural instability. Levodopa controls symptoms well early on but does not halt progression.
Interest in MSCs centres on anti-neuroinflammatory action and secretion of neurotrophic factors, which in animal models correlate with slower neuronal loss. Crossing the blood-brain barrier, however, remains a limitation requiring further proof.
EHL is also developing stem cell-derived exosomes — nanovesicles cells release to communicate — and lists Parkinson's among target applications, since small particles may reach neural tissue more readily than whole cells.
Bottom line for patients and families: PDSTEM has not reached human trials. Parkinson's patients should stay under neurologist care and be wary of services advertising a stem cell cure.
No. There is no curative therapy today; cell approaches are investigational and aim at slowing or easing symptoms.
Neural transplantation surgically implants cells into the brain; PDSTEM is intravenous and relies mainly on secreted factors.
They are smaller and easier to store, but clinical data remain very limited, so superiority cannot be claimed.
If the goal is PDSTEM specifically, it is too early. Seeing a Korean neurologist to optimise standard care is a reasonable alternative.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Cell drug pipeline · Brain & nerves